Prediction of Self-Report Cognitive Function for the Symptomatic Remission in Schizophrenia Treated with Amisulpride: a Multicenter, 8-Week Case-Control Study.

The Psychiatric quarterly Pub Date : 2021-09-01 Epub Date: 2021-01-03 DOI:10.1007/s11126-020-09877-5
Jia-Wu Ji, Li-Ying Liu, Kai-Rong Hao, Yin-Liang Yu, Sai-Zheng Weng, Jian-Fan Wu, Reng-Chun Huang
{"title":"Prediction of Self-Report Cognitive Function for the Symptomatic Remission in Schizophrenia Treated with Amisulpride: a Multicenter, 8-Week Case-Control Study.","authors":"Jia-Wu Ji,&nbsp;Li-Ying Liu,&nbsp;Kai-Rong Hao,&nbsp;Yin-Liang Yu,&nbsp;Sai-Zheng Weng,&nbsp;Jian-Fan Wu,&nbsp;Reng-Chun Huang","doi":"10.1007/s11126-020-09877-5","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to determine whether self-report cognitive function is a predictor of symptomatic remission in amisulpride-treated schizophrenia. Patients with DSM-IV schizophrenia diagnoses who received amisulpride treatment, were recruited. Each patient received amisulpride with a flexible-dose strategy of 400-800 mg daily for eight weeks. Remission was defined by a shorter version of the Positive and Negative Symptom Scale(PANSS)criteria, which includes six items (PANSS-6) with scores of less than three in each item(criteria A) or total six scores of less than fourteen(criteria B). Three hundred and three patients completed the study in 15 hospitals in China. By criteria A, 244 (80.5%) achieved symptomatic remission at endpoint, and 258 (85.1%) by criteria B. Duration of illness (DOI) (criteria A: t = 2.31, P = 0.025,criteria B:t = 2.24,p = 0.026) and perceived deficits questionnaire at baseline (PDQ20 Day0) (criteria A: t = 3.32, P = 0.001,criteria B:t = 2.76,p = 0.006) in remission groups were less than that in non-remission groups. Logistic regression analysis took into account sex, age, age-onset, DOI, and PDQ20(Day0), and showed that PDQ20(Day0) was a predictor for symptomatic remission in criteria A (B = - 0.02, P = 0.014) and criteria B (B = - 0.03, P = 0.005). The odds ratio (OR) of achieving remission will be reduced by 2% in criteria A and 3% in criteria B. There were no significant differences in gender composition, age, BMI, education level, age-onset, a daily dose of amisulpride and the percentage of PDQ20 Improvement between remission and nonremission in criteria A or criteria B. Receiver operating characteristic(ROC) curves were found for PDQ20(Day0) to define the precise scores to predict remission of schizophrenia (criteria A:AUC = 0.614, S.E. = 0.041, 95% CI = 0.535-0.694, p = 0.007; criteria B:AUC = 0.633, S.E. = 0.045, 95% CI = 0.545-0.721, p = 0.005). Our data suggest that an early self-report cognitive function in amisulpride-treated schizophrenia is important in predicting for symptomatic remission, the fewer scores of PDQ20 at baseline mean the patients have less daily cognitive difficulty, the more likely the patient is to achieve symptomatic remission.</p>","PeriodicalId":520814,"journal":{"name":"The Psychiatric quarterly","volume":" ","pages":"935-945"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11126-020-09877-5","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Psychiatric quarterly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11126-020-09877-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This study aimed to determine whether self-report cognitive function is a predictor of symptomatic remission in amisulpride-treated schizophrenia. Patients with DSM-IV schizophrenia diagnoses who received amisulpride treatment, were recruited. Each patient received amisulpride with a flexible-dose strategy of 400-800 mg daily for eight weeks. Remission was defined by a shorter version of the Positive and Negative Symptom Scale(PANSS)criteria, which includes six items (PANSS-6) with scores of less than three in each item(criteria A) or total six scores of less than fourteen(criteria B). Three hundred and three patients completed the study in 15 hospitals in China. By criteria A, 244 (80.5%) achieved symptomatic remission at endpoint, and 258 (85.1%) by criteria B. Duration of illness (DOI) (criteria A: t = 2.31, P = 0.025,criteria B:t = 2.24,p = 0.026) and perceived deficits questionnaire at baseline (PDQ20 Day0) (criteria A: t = 3.32, P = 0.001,criteria B:t = 2.76,p = 0.006) in remission groups were less than that in non-remission groups. Logistic regression analysis took into account sex, age, age-onset, DOI, and PDQ20(Day0), and showed that PDQ20(Day0) was a predictor for symptomatic remission in criteria A (B = - 0.02, P = 0.014) and criteria B (B = - 0.03, P = 0.005). The odds ratio (OR) of achieving remission will be reduced by 2% in criteria A and 3% in criteria B. There were no significant differences in gender composition, age, BMI, education level, age-onset, a daily dose of amisulpride and the percentage of PDQ20 Improvement between remission and nonremission in criteria A or criteria B. Receiver operating characteristic(ROC) curves were found for PDQ20(Day0) to define the precise scores to predict remission of schizophrenia (criteria A:AUC = 0.614, S.E. = 0.041, 95% CI = 0.535-0.694, p = 0.007; criteria B:AUC = 0.633, S.E. = 0.045, 95% CI = 0.545-0.721, p = 0.005). Our data suggest that an early self-report cognitive function in amisulpride-treated schizophrenia is important in predicting for symptomatic remission, the fewer scores of PDQ20 at baseline mean the patients have less daily cognitive difficulty, the more likely the patient is to achieve symptomatic remission.

预测自我报告的认知功能对阿米苏骄傲治疗的精神分裂症症状缓解的影响:一项多中心、8周的病例对照研究
本研究旨在确定自我报告的认知功能是否是阿米苏普利治疗的精神分裂症症状缓解的预测因子。被诊断患有DSM-IV精神分裂症并接受氨硫pride治疗的患者被招募。每位患者接受氨硫傲的灵活剂量策略,每天400-800毫克,持续8周。缓解由更短版本的阳性和阴性症状量表(PANSS)标准定义,该标准包括6个项目(PANSS-6),每个项目得分小于3分(标准a)或总共6个得分小于14分(标准B)。中国15家医院的303名患者完成了这项研究。根据标准A, 244人(80.5%)在终点达到症状缓解,根据标准B, 258人(85.1%)在终点达到症状缓解。缓解组的病程(DOI)(标准A: t = 2.31, P = 0.025,标准B:t = 2.24, P = 0.026)和基线时感知缺陷问卷(PDQ20 Day0)(标准A: t = 3.32, P = 0.001,标准B:t = 2.76, P = 0.006)小于非缓解组。Logistic回归分析考虑了性别、年龄、发病年龄、DOI和PDQ20(Day0),结果显示PDQ20(Day0)是标准a (B = - 0.02, P = 0.014)和标准B (B = - 0.03, P = 0.005)症状缓解的预测因子。在标准A中达到缓解的比值比(OR)将降低2%,在标准b中达到缓解的比值比(OR)将降低3%。在标准A或标准b中,性别组成、年龄、BMI、教育水平、发病年龄、阿米硫pride的每日剂量和缓解与非缓解之间的PDQ20改善百分比没有显著差异。S.E. = 0.041, 95% CI = 0.535 ~ 0.694, p = 0.007;标准B: AUC = 0.633, S.E. = 0.045, 95% CI -0.721 = 0.545, p = 0.005)。我们的数据表明,阿米苏普利治疗的精神分裂症患者早期自我报告的认知功能对预测症状缓解很重要,基线PDQ20得分越低意味着患者日常认知困难越少,患者越有可能实现症状缓解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信